<DOC>
	<DOCNO>NCT01937052</DOCNO>
	<brief_summary>The purpose project establish repository information sample breast cancer patient high risk develop breast cancer , initiate hormone therapy part standard clinical care prevention . This repository include patient report outcomes questionnaire , information medication use , data adherence hormone therapy tumor characteristic , include prospectively collect sample .</brief_summary>
	<brief_title>Johns Hopkins Breast Cancer Program Hormone Therapy Longitudinal Database</brief_title>
	<detailed_description>This research do learn side effect breast cancer hormone therapy person 's genetic information may help u develop way predict side effect patient may best treat . In addition , investigator hope look side effect hormone therapy influence patient 's willingness continue hormonal treatment . Men woman prescribe hormone therapy include Tamoxifen , Raloxifene ( Evista ) , Anastrozole ( Arimidex ) , Letrozole ( Femara ) , Exemestane ( Aromasin ) , oncologist either prevention breast cancer treatment breast cancer may join . The decision hormone therapy receive decision patient physician , study collect sample patient-reported outcome routine , standard care direct treatment decision intervention way .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Male female 18 year age old Physically cognitively able complete questionnaire Meet one follow category : 1 ) Initiating hormonal therapy breast cancer prevention . All patient plan initiate hormonal therapy either Tamoxifen , Raloxifene ( Evista速 ) , Anastrozole ( Arimidex速 ) , Letrozole ( Femara速 ) Exemestane ( Aromasin速 ) eligible ; concomitant use Zoladex Lupron permit ; 2 ) Patients histologically proven ductal carcinoma situ ( DCIS/stage 0 ) stage IIII invasive carcinoma breast estrogen ( ER ) and/or progesterone ( PR ) positive immunohistochemical staining , consider one list SERMs AIs . These patient must complete planned chemotherapy local therapy ( e.g. , lumpectomy mastectomy ) ; however , enrollment/initiation hormonal therapy study may do prior completion radiation and/or biologic therapy ( e.g. , trastuzumab ) discretion treat team ; , 3 ) The patient aware nature diagnosis , understand study regimen , requirement , risk , discomfort , able willing sign inform consent form . Patients transition one hormonal agent list another may enrol prior initiation new medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>